Cargando…

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease

BACKGROUND AND AIMS: When patients with sickle cell disease have appropriate indications, they can be prescribed hydroxyurea (HU) and deferasirox (DFX) concurrently despite little knowledge about how the two medications interact. We wished to analyze whether there was evidence of adverse interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Trisha E., Valle, Jhaqueline, Paulukonis, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279216/
https://www.ncbi.nlm.nih.gov/pubmed/34277954
http://dx.doi.org/10.1002/hsr2.323
_version_ 1783722412359024640
author Wong, Trisha E.
Valle, Jhaqueline
Paulukonis, Susan
author_facet Wong, Trisha E.
Valle, Jhaqueline
Paulukonis, Susan
author_sort Wong, Trisha E.
collection PubMed
description BACKGROUND AND AIMS: When patients with sickle cell disease have appropriate indications, they can be prescribed hydroxyurea (HU) and deferasirox (DFX) concurrently despite little knowledge about how the two medications interact. We wished to analyze whether there was evidence of adverse interaction between HU and DFX when taken simultaneously and hypothesized that those who took both drugs together had similar clinical complications when compared to those who took only one or neither drug. METHODS: We conducted this retrospective cohort investigation between 2009 and 2016 of persons with SCD in the California Sickle Cell Data Collection Program, a validated database of Californians with SCD a statewide. People in the database who took HU and DFX simultaneously for at least 3 months as compared to those who took either HU or DFX alone or to matched persons who took neither drug were eligible. RESULTS: We identified 104 people who were prescribed both HU and DFX concurrently, 877 who were prescribed HU only, and 314 who were prescribed DFX only during the study period. We identified 416 matched controls who took neither HU nor DFX. People who took both HU and DFX concurrently had similar rates of ED and inpatient encounters and had similar rates and distribution of adverse effects compared to those who took either HU or DFX alone or took neither drug. CONCLUSION: Three months of concurrent use of DFX and HU appears safe, but further studies are required to better understand the safety and effectiveness of this medication combination. (Funded by CDC, CDC Foundation, and others).
format Online
Article
Text
id pubmed-8279216
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82792162021-07-15 Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease Wong, Trisha E. Valle, Jhaqueline Paulukonis, Susan Health Sci Rep Research Articles BACKGROUND AND AIMS: When patients with sickle cell disease have appropriate indications, they can be prescribed hydroxyurea (HU) and deferasirox (DFX) concurrently despite little knowledge about how the two medications interact. We wished to analyze whether there was evidence of adverse interaction between HU and DFX when taken simultaneously and hypothesized that those who took both drugs together had similar clinical complications when compared to those who took only one or neither drug. METHODS: We conducted this retrospective cohort investigation between 2009 and 2016 of persons with SCD in the California Sickle Cell Data Collection Program, a validated database of Californians with SCD a statewide. People in the database who took HU and DFX simultaneously for at least 3 months as compared to those who took either HU or DFX alone or to matched persons who took neither drug were eligible. RESULTS: We identified 104 people who were prescribed both HU and DFX concurrently, 877 who were prescribed HU only, and 314 who were prescribed DFX only during the study period. We identified 416 matched controls who took neither HU nor DFX. People who took both HU and DFX concurrently had similar rates of ED and inpatient encounters and had similar rates and distribution of adverse effects compared to those who took either HU or DFX alone or took neither drug. CONCLUSION: Three months of concurrent use of DFX and HU appears safe, but further studies are required to better understand the safety and effectiveness of this medication combination. (Funded by CDC, CDC Foundation, and others). John Wiley and Sons Inc. 2021-07-14 /pmc/articles/PMC8279216/ /pubmed/34277954 http://dx.doi.org/10.1002/hsr2.323 Text en © 2021 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Wong, Trisha E.
Valle, Jhaqueline
Paulukonis, Susan
Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
title Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
title_full Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
title_fullStr Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
title_full_unstemmed Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
title_short Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
title_sort concurrent use of hydroxyurea and deferasirox in californians with sickle cell disease
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279216/
https://www.ncbi.nlm.nih.gov/pubmed/34277954
http://dx.doi.org/10.1002/hsr2.323
work_keys_str_mv AT wongtrishae concurrentuseofhydroxyureaanddeferasiroxincalifornianswithsicklecelldisease
AT vallejhaqueline concurrentuseofhydroxyureaanddeferasiroxincalifornianswithsicklecelldisease
AT paulukonissusan concurrentuseofhydroxyureaanddeferasiroxincalifornianswithsicklecelldisease